Cargando…
Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation
OBJECTIVES: A defect in bicarbonate secretion contributes to the pathophysiology of gastrointestinal complications in patients with cystic fibrosis (CF). We measured gastrointestinal pH, clinical outcomes, and intestinal transit profiles in patients with the G551D mutation before and after treatment...
Autores principales: | Gelfond, Daniel, Heltshe, Sonya, Ma, Changxing, Rowe, Steven M, Frederick, Carla, Uluer, Ahmet, Sicilian, Leonard, Konstan, Michael, Tullis, Elizabeth, Roach, R N Christine, Griffin, Katherine, Joseloff, Elizabeth, Borowitz, Drucy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387753/ https://www.ncbi.nlm.nih.gov/pubmed/28300821 http://dx.doi.org/10.1038/ctg.2017.10 |
Ejemplares similares
-
A small molecule CFTR potentiator restores ATP‐dependent channel gating to the cystic fibrosis mutant G551D‐CFTR
por: Liu, Jia, et al.
Publicado: (2022) -
Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) Potentiators Protect G551D but Not ΔF508 CFTR from Thermal
Instability
por: Liu, Xuehong, et al.
Publicado: (2014) -
Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass
por: Mouzaki, Marialena, et al.
Publicado: (2023) -
Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation
por: Bernarde, Cédric, et al.
Publicado: (2015) -
Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
por: Rowe, Steven M., et al.
Publicado: (2013)